Cargando…
673. Novel Delayed-Release Formulation of an Oral β-Lactamase Prevents Gut Microbiome Damage and Attenuates Antibiotic Resistance Caused by Oral Amoxicillin/Clavulanate without Interfering with Amoxicillin Systemic Absorption in Dogs
BACKGROUND: Exposure of the gut microbiota to antibiotics can alter the composition of the microbiome and lead to the emergence and spread of antibiotic resistance. SYN-004 (ribaxamase) is a clinical-stage β-lactamase intended to degrade certain IV β-lactam antibiotics in the GI tract to preserve th...
Autores principales: | Connelly, Sheila, Furlan-Freguia, Christian, Fanelli, Brian, Hasan, Nur A, Colwell, Rita R, Kaleko, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811160/ http://dx.doi.org/10.1093/ofid/ofz360.741 |
Ejemplares similares
-
SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs
por: Connelly, Sheila, et al.
Publicado: (2020) -
Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage
por: Connelly, Sheila, et al.
Publicado: (2019) -
620. Oral β-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance From IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis
por: Connelly, Sheila, et al.
Publicado: (2018) -
Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs
por: Connelly, Sheila, et al.
Publicado: (2019) -
Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy
por: Veeraraghavan, Balaji, et al.
Publicado: (2020)